Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Baldeon
 
SRCTN85216856
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
63/95 inconclusive 77%
ASCOT
 
NCT04483960
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
15/18 inconclusive -36%
Bennett-Guerrero
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
59/15 inconclusive -18% -23%
CCAP-2
 
NCT04345289
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
98/46 inconclusive 93%
Co-CLARITY
 
NCT04567173
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
13/12 inconclusive -7%
CONCOR-1
 
NCT04348656
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
625/313 safety concern 2% 14%
CONTAIN COVID-19
 
NCT04364737
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
468/473 inconclusive -12%
COP-COVID-19
 
NCT04358783
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
20/11 inconclusive -4%
DAWN-Plasma
 
NCT04429854
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
320/163 inconclusive -1% 1%
Holm K
 
NCT04600440
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
17/14 inconclusive -46%
Kirenga
 
NCT04542941
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
67/69 inconclusive 23%
Menichetti
 
NCT04716556
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
241/246 inconclusive -22% -11%
NCT04385199
 
NCT04385199
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
20/10 inconclusive -23%
NCT04397757
 
NCT04397757
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
41/39 suggested -76%
NCT04403477 (two doses)
 
NCT04403477
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
40/20 inconclusive -42%
NCT04442191
 
NCT04442191
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
8/6 inconclusive -80%
NCT04528368
 
NCT04528368
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
9/8 inconclusive -11%
PC/COVID-19
 
NCT04366245
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
38/36 inconclusive -33%
PERUCONPLASMA
 
NCT04497324
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
12/13 inconclusive -58%
RECOVERY (plasma)
 
NCT04381936
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
5795/5763 inconclusive 0% -1%
ConCOVID (Gharbharan et al.)
 
NCT04342182
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
43/43 inconclusive -5%
CONFIDENT
 
NCT04558476
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
150/151 inconclusive -14%
ConPlas-19
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
179/171 inconclusive -48% -4% -5%
COPLA-II trial
 
NCT04425915
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
200/200 suggested 15%
Salman
 
NCT04530370
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
15/15 inconclusive

COVID 19 all comers meta-analysis

LIFESAVER
 
NCT04374526
RCTconvalescent plasma treatmentstandard of careCOVID 19 all comerslow
4/8 inconclusive 90%

COVID-19 mild to moderate meta-analysis

Libster
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%

COVID-19 severe or critically meta-analysis

CAPSID
 
NCT04433910
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive -15% 52%
CP-COVID-19
 
NCT04332835
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
49/51 inconclusive 198%
O’Donnell
 
NCT04359810
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
Pouladzadeh
 
IRCT20200310046736N1
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
31/31 suggested -63% 568%
RECOVER
 
EudCT 2020-001632-10
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
43/47 inconclusive 8%
REMAP-CAP (plasma)
 
NCT02735707
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
1095/916 safety concern -4%
Sekine (PLACOVID)
 
NCT04547660
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
80/80 inconclusive 34% -5%
AlQahtani
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -47%
Li
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PlasmAr
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
Rasheed RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
21/28 inconclusive -79%
12 studies excluded by filtering options (6 RCT / 6 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).